Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free SBRA Stock Alerts

Sabra Healthcare REIT (SBRA) Financials

Sabra Healthcare REIT logo
$20.93 +0.07 (+0.34%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Sabra Healthcare REIT

Annual Income Statements for Sabra Healthcare REIT

This table shows Sabra Healthcare REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 69 60 148 269 69 138 -113 -78 14 127 156
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127 156
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 20 17 127 152
Total Pre-Tax Income 		80 71 159 288 79 156 81 22 19 128 153
Total Revenue		 241 265 320 625 647 586 437 518 649 706 788
Net Interest Income / (Expense)		 0.00 0.00 -88 0.00 0.00 0.00 -99 -105 0.00 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 88 0.00 0.00 0.00 99 105 0.00 0.00 0.00
Total Non-Interest Income		 241 265 408 625 647 586 535 623 649 706 788
Service Charges on Deposit Accounts		 3.51 7.79 26 - - 156 156 187 236 285 357
Other Service Charges		 28 38 18 91 212 14 18 36 38 40 58
Net Realized & Unrealized Capital Gains on Investments		 -0.16 -6.68 -0.55 -2.92 -16 -14 -35 -0.41 -1.54 0.00 -1.15
Other Non-Interest Income		 210 225 364 537 452 431 397 401 376 381 374
Provision for Credit Losses		 - - - - - - 3.94 0.14 0.19 -0.57 -1.05
Total Non-Interest Expense		 161 193 213 466 571 447 556 484 553 581 632
Other Operating Expenses		 16 18 32 37 31 33 35 40 47 50 54
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170 187
Impairment Charge		 0.00 30 1.33 1.41 122 4.00 9.50 94 14 18 7.32
Other Special Charges		 75 76 35 236 236 234 333 163 308 342 384
Nonoperating Income / (Expense), net		 - - 52 128 2.30 - 12 -12 -77 2.10 -3.52
Income Tax Expense		 0.75 1.05 0.65 3.01 3.40 0.71 1.85 1.24 2.00 1.01 1.84
Other Adjustments to Consolidated Net Income / (Loss)		 - - - - - - - -98 -2.90 -0.40 3.93
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.03 -0.07 -0.02 0.03 0.02 - - - 0.00 0.00 -0.10
Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54 $0.64
Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 206.22M 219.07M 230.95M 231.20M 233.50M 241.31M
Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54 $0.64
Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 207.25M 219.07M 230.95M 232.79M 236.05M 244.50M
Weighted Average Basic & Diluted Shares Outstanding		 62.30M 65.30M 105.80M 178.40M 205.27M 210.72M 230.90M 231.16M 231.48M 237.91M 252.15M
Cash Dividends to Common per Share		 $1.60 $1.67 $1.73 $1.80 $1.80 $1.35 $1.20 $1.20 $1.20 $1.20 $1.20

Quarterly Income Statements for Sabra Healthcare REIT

This table shows Sabra Healthcare REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 17 26 24 30 47 40 66 23 27 41 -25
Consolidated Net Income / (Loss)		 17 26 24 30 47 40 66 23 27 41 -25
Net Income / (Loss) Continuing Operations		 19 27 24 30 47 40 65 21 25 39 -27
Total Pre-Tax Income 		18 27 24 29 47 40 65 22 26 39 -27
Total Revenue		 135 139 147 149 156 156 176 159 296 193 203
Net Interest Income / (Expense)		 -28 -28 -29 -29 -28 -27 -28 -29 84 -28 -30
Total Interest Income		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Interest Expense		 28 28 29 29 28 27 28 29 -84 28 30
Long-Term Debt Interest Expense		 28 28 29 29 28 27 28 29 - 28 30
Total Non-Interest Income		 163 168 176 178 184 184 204 188 212 222 233
Service Charges on Deposit Accounts		 61 66 68 74 77 77 79 92 108 117 129
Other Service Charges		 9.13 9.70 9.18 9.70 11 10 25 12 11 9.96 3.07
Other Non-Interest Income		 93 92 99 95 96 96 100 85 93 95 101
Provision for Credit Losses		 -0.36 -0.14 -0.16 -0.15 -0.13 -0.17 -0.23 -0.24 -0.41 -0.21 102
Total Non-Interest Expense		 116 112 125 114 115 116 121 133 261 154 165
Other Operating Expenses		 17 12 13 12 13 13 13 13 16 15 17
Depreciation Expense		 43 43 42 43 42 43 44 49 51 53 56
Impairment Charge		 7.27 3.14 15 0.00 - 0.00 4.10 2.57 0.65 0.44 0.00
Other Special Charges		 49 54 55 59 59 60 61 70 193 86 92
Nonoperating Income / (Expense), net		 -0.73 - 1.78 -5.75 6.06 - 9.97 -4.43 - - 38
Income Tax Expense		 0.49 0.45 0.44 -0.27 0.38 0.41 0.50 0.44 0.49 0.53 0.68
Other Adjustments to Consolidated Net Income / (Loss)		 - -0.60 0.08 0.21 - 0.22 0.83 1.23 1.65 1.91 2.22
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - 0.00 - 0.00 0.00 -0.02 - -0.07 -0.05
Basic Earnings per Share		 $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.28 $0.09 $0.10 $0.16 ($0.10)
Weighted Average Basic Shares Outstanding		 231.20M 231.45M 231.62M 234.29M 233.50M 237.89M 237.98M 239.90M 241.31M 252.14M 252.27M
Diluted Earnings per Share		 $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.27 $0.09 $0.11 $0.16 ($0.10)
Weighted Average Diluted Shares Outstanding		 232.79M 233.37M 233.75M 237.04M 236.05M 240.30M 240.93M 243.56M 244.50M 255.97M 252.27M
Weighted Average Basic & Diluted Shares Outstanding		 231.48M 231.50M 234.26M 236.59M 237.91M 237.94M 239.79M 249.35M 252.15M 252.19M 255.46M

Annual Cash Flow Statements for Sabra Healthcare REIT

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -54 17 552 -527 -11 16 50 -62 -6.60 20 11
Net Cash From Operating Activities		 121 176 136 361 372 355 356 316 301 311 349
Net Cash From Continuing Operating Activities		 121 176 136 361 372 355 356 316 301 311 349
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 -78 14 127 156
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127 156
Provision For Loan Losses		 13 5.54 17 39 1.24 1.86 3.94 0.14 0.19 -0.57 -1.05
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170 187
Amortization Expense		 5.28 5.68 7.78 10 10 8.42 8.37 11 12 10 7.97
Non-Cash Adjustments to Reconcile Net Income		 -20 21 -73 -141 134 32 256 214 94 27 9.04
Changes in Operating Assets and Liabilities, net		 -20 4.97 -88 -18 -24 -2.74 23 -20 -2.73 -23 -9.85
Net Cash From Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109 -378
Net Cash From Continuing Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109 -378
Purchase of Property, Leasehold Improvements and Equipment		 -3.69 -1.00 -6.95 -28 -25 -47 -43 -54 -85 -55 -42
Purchase of Investment Securities		 -524 -171 -440 -672 -64 -111 -397 -267 -106 -162 -461
Sale and/or Maturity of Investments		 33 314 183 434 347 22 104 101 289 102 122
Other Investing Activities, net		 - - 3.76 6.87 5.08 0.00 0.00 4.60 5.46 5.94 2.53
Net Cash From Financing Activities		 314 -301 599 -629 -646 -202 30 -162 -410 -182 41
Net Cash From Continuing Financing Activities		 314 -300 599 -629 -646 -202 30 -162 -410 -182 41
Issuance of Debt		 289 69 434 0.00 639 0.00 792 204 -92 15 610
Issuance of Common Equity		 139 - - - 549 - 309 -4.81 -2.68 86 228
Repayment of Debt		 -3.13 -244 -4.15 -159 -1,483 -3.07 -798 -81 -1.98 -2.03 -505
Payment of Dividends		 -110 -119 -182 -325 -335 -278 -263 -277 -277 -280 -289
Other Financing Activities, Net		 -1.27 -5.94 351 -0.49 -16 -0.83 -9.32 -2.52 -36 -0.09 -2.36
Cash Interest Paid		 54 59 70 138 124 93 85 98 102 105 111
Cash Income Taxes Paid		 0.66 0.85 0.71 1.80 3.91 2.44 1.84 1.66 1.67 1.39 1.50

Quarterly Cash Flow Statements for Sabra Healthcare REIT

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 7.60 19 -24 27 -2.44 -37 73 106 -130 45 115
Net Cash From Operating Activities		 79 53 80 98 80 80 81 100 87 98 86
Net Cash From Continuing Operating Activities		 79 53 80 98 80 80 81 100 87 98 86
Net Income / (Loss) Continuing Operations		 17 26 24 30 47 40 66 23 27 41 -25
Consolidated Net Income / (Loss)		 17 26 24 30 47 40 66 23 27 41 -25
Provision For Loan Losses		 -0.36 -0.14 -0.16 -0.15 -0.13 -0.17 -0.23 -0.24 -0.41 -0.21 102
Depreciation Expense		 43 43 42 43 42 43 44 49 51 53 56
Amortization Expense		 3.09 3.07 3.07 2.61 1.73 1.73 1.73 2.15 2.36 2.37 2.37
Non-Cash Adjustments to Reconcile Net Income		 11 8.33 14 8.79 -3.89 2.44 -23 19 11 1.68 -37
Changes in Operating Assets and Liabilities, net		 4.91 -28 -2.05 14 -6.75 -7.53 -6.23 8.17 -4.27 0.58 -13
Net Cash From Investing Activities		 -62 -13 -57 -57 19 -16 -45 -200 -117 -105 87
Net Cash From Continuing Investing Activities		 -62 -13 -57 -57 19 -16 -45 -200 -117 -105 87
Purchase of Property, Leasehold Improvements and Equipment		 -21 -13 -12 -14 -16 -7.78 -5.79 -11 -17 -12 -13
Purchase of Investment Securities		 -41 -1.30 -56 -80 -19 -11 -55 -241 -155 -96 -196
Sale and/or Maturity of Investments		 -0.20 0.39 6.96 36 59 1.13 15 54 52 2.05 297
Other Investing Activities, net		 0.63 0.62 4.11 0.60 -5.32 0.81 0.56 -1.87 3.03 0.83 -1.23
Net Cash From Financing Activities		 -9.36 -20 -46 -14 -101 -101 37 206 -101 52 -57
Net Cash From Continuing Financing Activities		 -9.36 -20 -46 -14 -101 -101 37 206 -101 52 -57
Issuance of Debt		 61 52 -15 22 -59 -24 79 620 -65 138 -37
Issuance of Common Equity		 -0.49 -2.61 39 35 - -5.39 30 164 39 -8.25 56
Repayment of Debt		 -0.50 -0.50 -0.51 -0.51 14 -0.52 -0.52 -503 -0.53 -0.53 -0.54
Payment of Dividends		 -69 -69 -69 -70 -71 -71 -71 -72 -75 -76 -76
Other Financing Activities, Net		 -0.01 -0.08 - - -0.01 -0.08 - -2.29 0.01 -1.27 -0.12
Cash Interest Paid		 29 20 30 21 34 20 30 23 38 15 39

Annual Balance Sheets for Sabra Healthcare REIT

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304 5,493
Cash and Due from Banks		 7.43 26 519 50 39 59 112 49 41 60 72
Restricted Cash		 9.81 9.00 69 9.43 10 6.45 3.89 4.62 5.43 5.87 6.60
Trading Account Securities		 - - 0.00 340 319 289 97 135 137 122 118
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 2,040 2,010 5,994 5,854 5,341 5,285 5,163 4,959 4,617 4,514 4,686
Intangible Assets		 - 26 167 131 102 83 54 40 31 27 65
Other Assets		 300 195 283 281 258 263 537 559 554 574 545
Total Liabilities & Shareholders' Equity		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304 5,493
Total Liabilities		 1,415 1,250 3,595 3,411 2,581 2,576 2,587 2,691 2,584 2,562 2,670
Short-Term Debt		 255 26 641 624 - - 0.00 197 94 107 218
Other Short-Term Payables		 35 40 103 95 - 146 143 142 137 118 119
Long-Term Debt		 1,125 1,185 2,753 2,608 2,402 2,372 2,394 2,310 2,320 2,311 2,311
Other Long-Term Liabilities		 - 0.00 98 84 179 58 50 42 33 27 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,054 1,016 3,437 3,255 3,488 3,409 3,380 3,056 2,803 2,741 2,824
Total Preferred & Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741 2,822
Preferred Stock		 0.06 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741 2,822
Common Stock		 1,203 1,210 3,639 3,510 4,074 4,165 4,485 4,489 4,497 4,595 4,839
Accumulated Other Comprehensive Income / (Loss)		 -7.33 -1.80 11 12 -12 -40 -10 19 24 21 -3.57
Other Equity Adjustments		 -142 -192 -217 -272 -573 -716 -1,095 -1,452 -1,718 -1,875 -2,013
Noncontrolling Interest		 0.11 0.04 4.44 4.33 - - - - - 0.00 1.95

Quarterly Balance Sheets for Sabra Healthcare REIT

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 5,556 5,524 5,381 5,374 5,351 5,366 5,233 5,328 5,565 5,591 5,513
Cash and Due from Banks		 34 27 33 60 36 63 23 95 201 117 232
Restricted Cash		 5.15 5.15 5.60 6.00 5.91 5.97 6.24 6.48 6.92 6.92 6.76
Trading Account Securities		 139 140 136 132 130 131 121 126 118 117 114
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 4,797 4,752 4,603 4,577 4,566 4,574 4,488 4,479 4,630 4,703 4,832
Intangible Assets		 39 36 33 28 28 29 25 25 60 67 83
Other Assets		 542 564 570 571 585 563 571 596 550 581 245
Total Liabilities & Shareholders' Equity		 5,556 5,524 5,381 5,374 5,351 5,366 5,233 5,328 5,565 5,591 5,513
Total Liabilities		 2,580 2,581 2,512 2,607 2,589 2,621 2,531 2,617 2,738 2,803 2,760
Short-Term Debt		 80 101 33 146 130 153 83 163 282 355 317
Other Short-Term Payables		 143 122 128 113 113 123 112 113 124 118 115
Long-Term Debt		 2,317 2,320 2,317 2,317 2,316 2,318 2,311 2,317 2,309 2,310 2,309
Other Long-Term Liabilities		 40 39 34 31 30 28 25 24 23 20 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,827 2,788 2,752
Total Preferred & Common Equity		 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,825 2,786 2,751
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,825 2,786 2,751
Common Stock		 4,490 4,491 4,494 4,498 4,539 4,577 4,594 4,627 4,795 4,835 4,896
Accumulated Other Comprehensive Income / (Loss)		 17 32 40 31 31 17 15 -2.03 -5.98 0.69 6.10
Other Equity Adjustments		 -1,531 -1,580 -1,665 -1,762 -1,808 -1,849 -1,907 -1,914 -1,964 -2,050 -2,152
Noncontrolling Interest		 - - - - - - - - 2.02 1.88 1.72

Annual Metrics And Ratios for Sabra Healthcare REIT

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 249,349,673.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 249,349,673.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.62
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54 $0.64
Adjusted Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 0.00 219.07M 230.95M 231.20M 233.50M 241.31M
Adjusted Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54 $0.64
Adjusted Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 0.00 219.07M 230.95M 232.79M 236.05M 244.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.37 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.19M 65.29M 178.26M 178.32M 205.27M 0.00 230.90M 231.16M 231.48M 237.91M 252.15M
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Sabra Healthcare REIT

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - 249,349,673.00 252,145,717.00 252,190,095.00
DEI Adjusted Shares Outstanding		 - - - - - - - - 249,349,673.00 252,145,717.00 252,190,095.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - 0.11 0.16 -0.10
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -1.17% 5.71% 10.59% 9.46% 15.26% 12.50% 20.02% 7.19% - 23.52% 15.37%
EBITDA Growth		 -10.11% 5.97% -12.84% 1.92% 30.02% 16.97% 49.39% -4.43% - 10.74% -105.73%
EBIT Growth		 -3.19% 109.37% -24.81% 7.71% 108.72% 48.34% 144.87% -25.38% - -2.65% -216.80%
NOPAT Growth		 76.83% 182.15% -25.06% 55.27% 118.88% 49.30% 147.45% -27.53% - -2.96% -182.39%
Net Income Growth		 120.20% 376.74% 13.15% 297.26% 172.18% 53.52% 173.38% -24.41% - 1.26% -138.52%
EPS Growth		 121.62% 375.00% 11.11% 285.71% 150.00% 54.55% 170.00% -30.77% - -5.88% -137.04%
Operating Cash Flow Growth		 16.50% -22.69% 13.93% 17.35% 1.56% 52.03% 1.04% 2.37% - 22.55% 6.00%
Free Cash Flow Firm Growth		 64.95% -52.45% -61.76% -91.60% -73.03% 3.18% -59.25% -559.13% - -282.24% -421.93%
Invested Capital Growth		 -6.23% -2.65% -2.89% -0.06% -1.11% -2.57% -0.33% 3.89% - 7.00% 3.61%
Revenue Q/Q Growth		 -0.16% 2.67% 5.61% 1.11% 5.13% 0.21% 12.67% -9.70% - -34.59% 5.23%
EBITDA Q/Q Growth		 -16.40% 14.13% -7.41% 19.43% 6.66% -0.02% 17.29% -23.60% - 6.88% -106.07%
EBIT Q/Q Growth		 -38.61% 50.65% -15.54% 55.41% 18.97% -2.88% 36.38% -52.64% - 12.49% -263.62%
NOPAT Q/Q Growth		 -18.22% 44.12% -17.50% 59.68% 15.28% -1.69% 36.74% -53.24% - 52.58% -216.08%
Net Income Q/Q Growth		 213.61% 53.03% -8.68% 24.25% 56.76% -13.69% 62.62% -65.64% - 50.34% -161.86%
EPS Q/Q Growth		 214.29% 37.50% -9.09% 30.00% 53.85% -15.00% 58.82% -66.67% - 45.45% -162.50%
Operating Cash Flow Q/Q Growth		 -5.38% -32.95% 51.77% 21.87% -18.11% 0.37% 0.87% 23.47% - 12.51% -12.75%
Free Cash Flow Firm Q/Q Growth		 -20.64% -53.68% 4.85% -78.21% 154.79% 77.21% -58.59% -345.59% - -89.02% 26.86%
Invested Capital Q/Q Growth		 -0.03% 0.27% -0.42% 0.12% -1.08% -1.22% 1.86% 4.37% - 1.88% -1.37%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 48.67% 52.26% 45.82% 54.12% 54.90% 54.78% 57.03% 48.25% - 49.11% -2.83%
EBIT Margin		 14.75% 19.20% 15.35% 23.60% 26.70% 25.88% 31.33% 16.43% - 20.40% -31.72%
Profit (Net Income) Margin		 12.66% 18.87% 16.32% 20.05% 29.90% 25.76% 37.17% 14.14% - 21.12% -12.41%
Tax Burden Percent		 93.19% 96.16% 98.53% 101.63% 98.99% 99.52% 100.51% 103.64% - 103.52% 94.23%
Interest Burden Percent		 92.14% 102.23% 107.87% 83.61% 113.11% 100.00% 118.06% 83.06% - 100.00% 41.53%
Effective Tax Rate		 2.68% 1.66% 1.80% -0.90% 0.81% 1.02% 0.76% 2.01% - 1.33% 0.00%
Return on Invested Capital (ROIC)		 1.37% 1.98% 1.59% 2.60% 2.97% 3.02% 3.81% 1.96% - 3.15% -3.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 1.31% 1.95% 1.66% 2.37% 3.22% 3.03% 4.25% 1.84% - 3.22% -2.80%
Return on Net Nonoperating Assets (RNNOA)		 1.10% 1.65% 1.42% 2.04% 2.80% 2.69% 3.82% 1.67% - 2.97% -2.61%
Return on Equity (ROE)		 2.46% 3.63% 3.01% 4.64% 5.78% 5.70% 7.63% 3.63% - 6.11% -6.19%
Cash Return on Invested Capital (CROIC)		 8.01% 4.67% 4.79% 2.04% 3.52% 5.32% 3.82% -0.57% - -3.92% -2.45%
Operating Return on Assets (OROA)		 1.42% 1.91% 1.57% 2.50% 2.95% 2.97% 3.74% 1.95% - 3.11% -4.98%
Return on Assets (ROA)		 1.22% 1.88% 1.67% 2.13% 3.30% 2.95% 4.44% 1.68% - 3.22% -1.95%
Return on Common Equity (ROCE)		 2.46% 3.63% 3.01% 4.64% 5.78% 5.70% 7.63% 3.63% - 6.11% -6.19%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 1.79% 1.89% 3.54% 0.00% 5.21% 6.72% 6.20% - 5.60% 2.37%
Net Operating Profit after Tax (NOPAT)		 19 27 22 35 41 40 55 26 - 39 -45
NOPAT Margin		 13.75% 19.30% 15.08% 23.81% 26.11% 25.62% 31.09% 16.10% - 20.13% -22.20%
Net Nonoperating Expense Percent (NNEP)		 0.06% 0.02% -0.08% 0.23% -0.25% -0.01% -0.44% 0.12% - -0.08% -0.78%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 85.52% 80.90% 84.76% 76.50% 73.38% 74.23% 68.80% 83.72% - 79.71% 81.35%
Earnings before Interest and Taxes (EBIT)		 20 27 23 35 42 40 55 26 - 39 -65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 66 73 67 80 86 86 101 77 - 95 -5.76
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.07 1.19 1.27 1.59 1.47 1.54 1.62 1.58 - 1.74 1.79
Price to Tangible Book Value (P/TBV)		 1.08 1.20 1.28 1.61 1.48 1.55 1.63 1.62 - 1.78 1.84
Price to Revenue (P/Rev)		 5.60 6.04 6.28 7.65 6.81 6.84 6.88 6.90 - 5.88 5.78
Price to Earnings (P/E)		 217.85 66.31 66.92 44.86 31.76 29.53 24.06 25.53 - 31.05 75.19
Dividend Yield		 9.26% 8.45% 7.94% 6.45% 7.06% 6.87% 6.51% 6.44% - 6.24% 6.15%
Earnings Yield		 0.46% 1.51% 1.49% 2.23% 3.15% 3.39% 4.16% 3.92% - 3.22% 1.33%
Enterprise Value to Invested Capital (EV/IC)		 1.03 1.09 1.13 1.30 1.24 1.28 1.30 1.27 - 1.36 1.36
Enterprise Value to Revenue (EV/Rev)		 10.02 10.46 10.59 11.86 10.79 10.72 10.61 10.58 - 8.97 8.59
Enterprise Value to EBITDA (EV/EBITDA)		 18.46 19.46 20.94 23.85 20.83 20.47 19.23 19.69 - 20.47 28.69
Enterprise Value to EBIT (EV/EBIT)		 56.30 53.42 59.70 66.68 50.59 46.84 39.36 42.06 - 47.43 202.36
Enterprise Value to NOPAT (EV/NOPAT)		 63.07 53.84 60.11 65.71 50.99 46.47 37.35 39.65 - 49.15 125.57
Enterprise Value to Operating Cash Flow (EV/OCF)		 17.85 19.92 20.02 21.86 20.53 19.29 19.97 20.09 - 20.16 19.67
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.43 22.92 23.30 63.68 34.89 23.73 34.07 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.86 0.89 0.89 0.90 0.88 0.89 0.91 0.92 - 0.96 0.95
Long-Term Debt to Equity		 0.83 0.84 0.84 0.84 0.84 0.86 0.85 0.82 - 0.83 0.84
Financial Leverage		 0.84 0.85 0.85 0.86 0.87 0.89 0.90 0.91 - 0.92 0.93
Leverage Ratio		 1.90 1.90 1.91 1.91 1.93 1.94 1.95 1.96 - 1.97 1.98
Compound Leverage Factor		 1.75 1.95 2.06 1.60 2.18 1.94 2.30 1.63 - 1.97 0.82
Debt to Total Capital		 46.28% 47.10% 46.97% 47.37% 46.86% 46.97% 47.77% 47.82% - 48.87% 48.83%
Short-Term Debt to Total Capital		 1.81% 2.79% 2.50% 2.93% 2.07% 1.62% 3.14% 5.21% - 6.51% 5.90%
Long-Term Debt to Total Capital		 44.47% 44.30% 44.47% 44.44% 44.80% 45.35% 44.63% 42.62% - 42.36% 42.92%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% - 0.03% 0.03%
Common Equity to Total Capital		 53.72% 52.90% 53.03% 52.63% 53.14% 53.03% 52.23% 52.14% - 51.09% 51.14%
Debt to EBITDA		 8.31 8.44 8.68 8.72 7.90 7.51 7.05 7.44 - 7.38 10.31
Net Debt to EBITDA		 8.15 8.22 8.53 8.47 7.68 7.42 6.76 6.85 - 7.04 9.37
Long-Term Debt to EBITDA		 7.98 7.94 8.22 8.18 7.55 7.26 6.59 6.63 - 6.40 9.06
Debt to NOPAT		 28.38 23.35 24.91 24.01 19.34 17.06 13.69 14.99 - 17.72 45.11
Net Debt to NOPAT		 27.83 22.73 24.48 23.34 18.81 16.85 13.13 13.79 - 16.90 41.02
Long-Term Debt to NOPAT		 27.27 21.97 23.58 22.53 18.48 16.47 12.79 13.36 - 15.36 39.66
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% - 0.03% 0.03%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 365 169 177 39 98 175 72 -177 - -318 -233
Operating Cash Flow to CapEx		 373.85% 408.16% 644.89% 706.12% 515.16% 1,031.26% 1,399.22% 941.81% - 829.99% 644.83%
Free Cash Flow to Firm to Interest Expense		 13.07 5.95 6.05 1.31 3.51 6.44 2.62 -6.14 - -11.19 -7.81
Operating Cash Flow to Interest Expense		 2.82 1.86 2.73 3.31 2.85 2.96 2.94 3.46 - 3.46 2.88
Operating Cash Flow Less CapEx to Interest Expense		 2.06 1.40 2.31 2.84 2.29 2.67 2.73 3.09 - 3.05 2.44
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.12 - 0.15 0.16
Fixed Asset Turnover		 0.11 0.12 0.12 0.12 0.13 0.13 0.14 0.14 - 0.18 0.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,217 5,231 5,209 5,215 5,159 5,096 5,191 5,418 - 5,453 5,379
Invested Capital Turnover		 0.10 0.10 0.11 0.11 0.11 0.12 0.12 0.12 - 0.16 0.16
Increase / (Decrease) in Invested Capital		 -347 -142 -155 -3.28 -58 -134 -17 203 - 357 187
Enterprise Value (EV)		 5,364 5,680 5,903 6,761 6,375 6,521 6,766 6,855 - 7,392 7,310
Market Capitalization		 2,997 3,282 3,499 4,360 4,024 4,156 4,388 4,470 - 4,849 4,920
Book Value per Share		 $12.12 $11.96 $11.93 $11.72 $11.59 $11.36 $11.40 $11.78 - $11.05 $10.91
Tangible Book Value per Share		 $11.99 $11.83 $11.81 $11.59 $11.47 $11.25 $11.29 $11.53 - $10.78 $10.58
Total Capital		 5,217 5,231 5,209 5,215 5,159 5,096 5,191 5,418 - 5,453 5,379
Total Debt		 2,414 2,463 2,447 2,470 2,418 2,394 2,480 2,591 - 2,665 2,626
Total Long-Term Debt		 2,320 2,317 2,316 2,318 2,311 2,311 2,317 2,309 - 2,310 2,309
Net Debt		 2,367 2,397 2,404 2,401 2,351 2,365 2,378 2,384 - 2,542 2,388
Capital Expenditures (CapEx)		 21 13 12 14 16 7.78 5.79 11 - 12 13
Net Nonoperating Expense (NNE)		 1.47 0.60 -1.82 5.58 -5.92 -0.22 -11 3.12 - -1.91 -20
Net Nonoperating Obligations (NNO)		 2,414 2,463 2,447 2,470 2,418 2,394 2,480 2,591 - 2,665 2,626
Total Depreciation and Amortization (D&A)		 46 46 45 45 44 45 45 51 - 55 59
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.28 $0.09 $0.10 $0.16 ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 231.20M 231.45M 231.62M 234.29M 233.50M 237.89M 237.98M 239.90M 241.31M 252.14M 252.27M
Adjusted Diluted Earnings per Share		 $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.27 $0.09 $0.11 $0.16 ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 232.79M 233.37M 233.75M 237.04M 236.05M 240.30M 240.93M 243.56M 244.50M 255.97M 252.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 231.48M 231.50M 234.26M 236.59M 237.91M 237.94M 239.79M 249.35M 252.15M 252.19M 255.46M
Normalized Net Operating Profit after Tax (NOPAT)		 73 84 91 65 100 99 120 96 - 124 19
Normalized NOPAT Margin		 54.20% 60.11% 61.93% 44.09% 63.74% 63.53% 67.79% 60.55% - 64.07% 9.55%
Pre Tax Income Margin		 13.59% 19.63% 16.56% 19.73% 30.21% 25.88% 36.98% 13.65% - 20.40% -13.17%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.72 0.94 0.77 1.19 1.49 1.49 2.01 0.91 - 1.39 -2.17
NOPAT to Interest Expense		 0.67 0.95 0.76 1.20 1.45 1.48 1.99 0.89 - 1.37 -1.52
EBIT Less CapEx to Interest Expense		 -0.04 0.48 0.35 0.72 0.93 1.21 1.79 0.54 - 0.97 -2.61
NOPAT Less CapEx to Interest Expense		 -0.09 0.49 0.33 0.73 0.90 1.19 1.78 0.52 - 0.95 -1.96
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 2,016.92% 560.72% 531.00% 286.65% 221.09% 200.39% 155.77% 163.18% - 188.30% 456.94%
Augmented Payout Ratio		 2,016.92% 560.72% 531.00% 286.65% 153.13% 200.39% 155.77% 163.18% - 188.30% 456.94%

Financials Breakdown Chart

Key Financial Trends

Sabra Health Care REIT’s financial statements show a mixed operating trend through the second quarter of 2026. Revenue increased from $132.8 million in Q2 2023 to $203.4 million in Q2 2026, supported primarily by growth in service-charge and other non-interest income. However, earnings have been volatile, with quarterly net income ranging from a $50.1 million loss in Q3 2022 to a $65.5 million profit in Q2 2025, followed by a $25.2 million loss in Q2 2026.

Cash generation has been more consistent than reported earnings. Operating cash flow remained positive in every quarter provided, generally ranging between approximately $70 million and $100 million. Sabra generated $85.8 million of operating cash flow in Q2 2026, although this included a substantial $102.4 million provision for credit losses added back as a non-cash expense. The company also ended Q2 2026 with approximately $352.2 million of cash, restricted cash and trading securities, up meaningfully from the comparable Q2 2025 balance.

The balance sheet remains heavily leveraged, while shareholder dilution and recurring special charges are important risks. Total debt increased to approximately $2.63 billion in Q2 2026 from roughly $2.45 billion in Q2 2024. Common shares used in calculating basic earnings per share increased to 252.3 million in Q2 2026 from 231.6 million in Q2 2024. The Q2 2026 figures also include a large credit-loss provision and $92.3 million of special charges, resulting in negative earnings despite positive operating cash flow.

  • Revenue has expanded: Total revenue rose from $132.8 million in Q2 2023 to $203.4 million in Q2 2026, a gain of more than 50% over the period.
  • Operating cash flow remains positive: Sabra generated $85.8 million in operating cash flow in Q2 2026, following $98.4 million in Q1 2026 and $87.4 million in Q4 2025.
  • Liquidity improved during Q2 2026: Cash and due from banks increased to $231.6 million from $116.5 million in Q1 2026. Including restricted cash and trading securities, liquid resources were approximately $352.2 million.
  • Property assets have grown: Premises and equipment increased to $4.84 billion in Q2 2026 from $4.48 billion in Q2 2025, indicating continued investment in the real estate portfolio.
  • Credit-loss provisions have historically been limited: Provisions were modest in most reported quarters through Q1 2026, suggesting that the unusually large $102.4 million Q2 2026 provision was a major one-quarter event rather than a consistent historical pattern.
  • Investment activity is volatile: Sabra has frequently purchased and sold investment securities. In Q2 2026, $195.7 million of purchases were more than offset by $296.8 million of sales and maturities, producing positive investing cash flow but making quarter-to-quarter cash trends less indicative of recurring operations.
  • Reported figures include restatements and calculated periods: Several earlier income and cash-flow statements are identified as restated or calculated, so investors should rely on the company’s latest filings when making detailed year-over-year comparisons.
  • Q2 2026 earnings turned negative: Sabra reported a $25.2 million net loss attributable to common shareholders, or negative $0.10 per diluted share, compared with $40.9 million of net income and $0.16 per share in Q1 2026.
  • Special charges remain a recurring burden: Other special charges increased from $48.7 million in Q2 2023 to $92.3 million in Q2 2026, after reaching $192.9 million in Q4 2025. These charges have repeatedly reduced reported profitability.
  • Debt and dilution have increased: Total short- and long-term debt reached approximately $2.63 billion in Q2 2026, while basic shares outstanding rose to 252.3 million from 231.6 million in Q2 2024. Both trends can constrain per-share earnings and increase financial risk.
09/04/26 12:14 AM ETAI Generated. May Contain Errors.

Sabra Healthcare REIT Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sabra Healthcare REIT's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Sabra Healthcare REIT's net income appears to be on a downward trend, with a most recent value of $155.51 million in 2025, rising from $79.38 million in 2015. The previous period was $126.71 million in 2024. See Sabra Healthcare REIT's forecast for analyst expectations on what's next for the company.

Over the last 10 years, Sabra Healthcare REIT's total revenue changed from $240.96 million in 2015 to $787.51 million in 2025, a change of 226.8%.

Sabra Healthcare REIT's total liabilities were at $2.67 billion at the end of 2025, a 4.2% increase from 2024, and a 88.7% increase since 2015.

In the past 10 years, Sabra Healthcare REIT's cash and equivalents has ranged from $7.43 million in 2015 to $518.63 million in 2017, and is currently $71.54 million as of their latest financial filing in 2025.


Related Companies

Financial statements for NASDAQ:SBRA last updated on 8/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel